Abstract | BACKGROUND: RESULTS: Here, we investigated the in vivo therapeutic effects of the two xanthones in a xenograft murine model of human CLL, developed by engrafting CD5-transfected chronic leukemia B cells into SCID mice. Treatment of the animals with five daily injections of either allanxanthone C or macluraxanthone resulted in a significant prolongation of their survival as compared to control animals injected with the solvent alone (p = 0.0006 and p = 0.0141, respectively). The same treatment of mice which were not xenografted induced no mortality. CONCLUSION: These data show for the first time the in vivo antileukemic activities of two plant-derived xanthones, and confirm their potential interest for CLL therapy.
|
Authors | Séverine Loisel, Karine Le Ster, Michèle Meyer, Christian Berthou, Pierre Youinou, Jean-Pierre Kolb, Christian Billard |
Journal | Journal of hematology & oncology
(J Hematol Oncol)
Vol. 3
Pg. 49
(Dec 07 2010)
ISSN: 1756-8722 [Electronic] England |
PMID | 21138552
(Publication Type: Journal Article)
|
Chemical References |
- Xanthones
- allanxanthone C
|
Topics |
- Animals
- Cell Line, Tumor
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy)
- Mice
- Mice, SCID
- Xanthones
(pharmacology)
- Xenograft Model Antitumor Assays
|